Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic / 전남의대학술지
My-Dung HOANG; Sung-Hoon JUNG; Hyun-Ju LEE; Youn-Kyung LEE; Thanh-Nhan NGUYEN-PHAM; Nu-Ri CHOI; Manh-Cuong VO; Seung-Shin LEE; Jae-Sook AHN; Deok-Hwan YANG; Yeo-Kyeoung KIM; Hyeoung-Joon KIM; Je-Jung LEE.
Chonnam Medical Journal
; : 1-7, 2015.
Artículo
en Inglés
| WPRIM | ID: wpr-133657
Although the introduction of stem cell transplantation and novel agents has improved survival, multiple myeloma (MM) is still difficult to cure. Alternative approaches are clearly needed to prolong the survival of patients with MM. Dendritic cell (DC) therapy is a very promising tool immunologically in MM. We developed a method to generate potent DCs with increased Th1 polarization and migration ability for inducing strong myeloma-specific cytotoxic T lymphocytes. In this review, we discuss how the efficacy of cancer immunotherapy using DCs can be improved in MM.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados